Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising new combo offers hope for aggressive lymphoma that stopped responding to treatment

NCT ID NCT07372352

Recruiting now Disease control Sponsor: The First Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

First seen Feb 01, 2026 · Last updated Jun 17, 2026 · Updated 22 times

Summary

This study tests a combination of three drugs (zeprumetostat, azacitidine, and mitoxantrone hydrochloride liposome) in about 26 adults with peripheral T-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if this mix can shrink tumors and help people live longer without the cancer growing. Participants will receive up to 6 cycles of the combo, then up to 2 years of a single maintenance drug if they respond. The trial closely tracks both benefits and side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIPHERAL T CELLS LYMPHOMA (PTCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of Soochow University

    RECRUITING

    Suzhou, Jiangsu, 215000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

mature T-cell and NK-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PERIPHERAL T CELLS LYMPHOMA (PTCL)